医学部医学科について | 東北大学大学院医学系研究科・医学部

STAFF

Professor

Endo, HidenoriProfessor. MD, PhD. 遠藤英徳教授

Other Faculty / Staff

Kanamori, Masayuki
Assoc. Prof.MD, PhD. 金森政之准教授

CONTACT

TEL：+81-22-717-7230
E-MAIL：edu*nsg.med.tohoku.ac.jp
（「*」を「@」に変換してください）

WEBSITE

OUTLINE

Cerebrovascular Disease
In clinical research, the results of a clinical trial for subarachnoid hemorrhage, which was led by Tohoku University, have recently been acknowledged, resulting in the approval of a new drug for clinical use. Our research on moyamoya disease, a clinical condition named by our first head professor, Dr. Jiro Suzuki, has kept progressing, and we have reached many impactful findings on changes in cerebral circulation after revascularization surgery for moyamoya disease. In basic research, we were the first to identify a susceptibility gene for Moyamoya disease, and we are conducting research on it using genetically engineered mice and patient-derived iPS cells. Another focus of ours is research on neuroregenerative medicine as a novel treatment for cerebrovascular diseases.

Brain Tumor
We conduct a wide range of research aimed at improving treatment outcomes for patients with brain tumors. With the consent of patients, we conduct genetic analysis of surgically removed brain tumors to analyze the causes and pathology of brain tumors. As a result, we have found that anticancer drugs are highly effective in patients with specific genetic abnormalities, and these results have been applied to treatment.

Regenerative Medicine
For decades, stem cell therapy has been sought after as a solution to treat numerous diseases. MUSE (Multilineage Stress-Enduring) stem cells are endogenous pluripotent-like stem cells. They are naturally occurring cells, found in the bone marrow, peripheral blood, and connective tissues of organs and are thus non-tumorigenic. In our lab, we carry out extensive work on the utility of MUSE stem cells in treating neurological diseases. Our ongoing work focuses on ischemic and hemorrhagic strokes as well as traumatic brain and spinal cord injuries. Our ongoing work focuses on developing novel methods for the preparation and optimization of MUSE stem cell delivery, the expansion of MUSE cell application to various diseases, and understanding the basic biology by which MUSE stem cells offer neuroprotective benefits.

脳血管障害
臨床研究では、近年、東北大学が中心としてとりまとめた、くも膜下出血の治験の成果が認められて、新規薬剤が承認となりました。また、当科初代教授の鈴木二郎先生が命名した、もやもや病についても継続した研究がなされており、もやもや病に対する血行再建術後の、脳循環における変化について、多くの成果を収めてきました。基礎研究では、もやもや病疾患感受性遺伝子を初めて同定し、遺伝子改変マウスを用いた研究や、患者由来のiPS細胞を用いた研究を行っています。また、脳血管疾患に対する新規の治療として、神経再生医療に関する研究にも力を入れています。

脳腫瘍
手術により摘出した脳腫瘍の遺伝子解析をおこない、脳腫瘍の原因、病態解析を行っています。その結果、特定遺伝子の異常をもった患者さんにおいては抗がん剤の効果が高いことが示され治療に応用されています。

医療機器開発
新しい手術用医療機器（パルスウォータージェットメス）として、これまで企業、学術機関と共同研究を脳神経外科領域だけでなく、さまざまな領域（脊椎脊髄外科 / 消化管外科 / 泌尿器科 / 心臓血管外科 / 眼科 / 形成外科 / 皮膚科 / 歯科）で非臨床試験、臨床試験を実施してきました。

集合写真

ARTICLE

Omodaka S, Sugiyama SI, Sakata H, et al. Aneurysm Wall Enhancement Can Predict Rupture Point in Intracranial Aneurysms With Multiple Blebs. Neurosurgery. 2024 Aug 8. doi:10.1227/neu.0000000000003134. Epub ahead of print. PMID: 39115321.

Tashiro R, Anzawa R, Inoue T, et al. The prognostic values of plasma desmosines, crosslinking molecules of elastic fibers, in the disease progression of Moyamoya disease. Bioorg Med Chem. 2024 Feb 15;100:117602. doi:10.1016/j.bmc.2024.117602. Epub 2024 Feb 1. PMID: 38324946.

Niizuma K, Osawa SI, Endo H, et al. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke. J Cereb Blood Flow Metab. 2023 Dec;43(12):2029-2039. doi: 10.1177/0271678X231202594. Epub 2023 Sep 27. PMID: 37756573; PMCID: PMC10925866.

Endo H, Hagihara Y, Kimura N, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022 Apr 1;137(6):1707-1717. doi: 10.3171/2022.2.JNS212914. PMID: 35364589.

Kanamori M, Mugikura S, Iizuka O, et al. Clinical significance of cerebral microbleeds in patients with germinoma who underwent long-term follow-up. J Neurooncol. 2024 Aug 12. doi: 10.1007/s11060-024-04753-9. Epub ahead of print. PMID: 39133380.

東北大学大学院医学系研究科・医学部

医科学専攻

Neurosurgery神経外科学